Lotte Biologics recently marked a significant milestone in the construction of its first plant at the Songdo Bio Campus with a topping-out ceremony. The event, held on September 10, was a momentous occasion for the biotech company as it aims to achieve commercial production at the site by 2027. The Songdo Bio Campus, located in the Advanced Industry Cluster of Songdo International City, Incheon, is set to become a key hub for biopharmaceutical production.
The ceremony, attended by key executives and employees from Lotte Biologics and the Lotte Group, symbolizes the completion of the framework of the first plant within just 18 months of commencing construction. The traditional topping-out event involved the installation of the ridge beam, the highest structural member of the roof, and the placement of a “topping-out document” on the building, signifying the completion of this phase of the project and wishing for its success and safety.
The establishment of the Songdo Bio Campus underscores Lotte Biologics’ commitment to expanding its production capacity and enhancing its capabilities in antibody drug manufacturing. The campus is envisioned to house three production facilities, each with a capacity of 120,000 liters. The first plant, scheduled for completion in 2026, is designed to be a state-of-the-art antibody drug manufacturing facility, leveraging cutting-edge technology to ensure production efficiency and quality management.
With a long-term vision to position the Songdo Bio Campus as a global leader in biopharmaceutical production, Lotte Biologics is focused on creating a “smart factory” that integrates advanced technologies to meet the evolving needs of the industry. The company aims to be at the forefront of the Contract Development and Manufacturing Organization (CDMO) market, emphasizing efficiency and flexibility in its operations.
The strategic location of the Songdo Bio Campus, complemented by Lotte Biologics’ existing facility in Syracuse, New York, is expected to enhance operational synergy and enable the company to cater to a wide range of client requirements. The Syracuse Bio Campus serves as a comprehensive CDMO hub, while the Songdo facility will serve as a mass production base, further expanding Lotte Biologics’ global reach and impact.
In addition to its infrastructure development, Lotte Biologics has been actively engaging with global partners, securing multiple contracts in the biotech industry. The company’s recent collaborations with US-based and UK-based biotech firms underscore its growing presence in the international market. By investing in cutting-edge facilities and forging strategic partnerships, Lotte Biologics is positioning itself as a key player in the biopharmaceutical landscape.
The completion of the ADC production facility at the Syracuse Bio Campus earlier this year exemplifies Lotte Biologics’ commitment to innovation and quality. Equipped with advanced production and purification lines, the facility offers a range of services, including in-house quality control testing and characterization analysis. The adoption of a flexible, disposable system enables the company to meet diverse client needs efficiently.
As Lotte Biologics embarks on the next phase of its growth journey, the topping-out ceremony at the Songdo Bio Campus serves as a symbolic moment of achievement and progress. The company’s dedication to advancing biopharmaceutical production and contributing to the improvement of human health underscores its leadership in the industry. With a strong focus on technological advancement and global collaboration, Lotte Biologics is poised to shape the future of biotech innovation and manufacturing.
Key takeaways:
– Lotte Biologics celebrates the topping-out ceremony at its Songdo Bio Campus, marking a milestone in the construction of its first plant.
– The company aims to achieve commercial production at the site by 2027 and position the campus as a hub for biopharmaceutical production.
– With a focus on efficiency and flexibility, Lotte Biologics is leveraging advanced technologies to enhance its capabilities in antibody drug manufacturing.
– Strategic partnerships with global biotech firms and investments in state-of-the-art facilities underscore Lotte Biologics’ commitment to industry leadership.
– The completion of the ADC production facility at the Syracuse Bio Campus highlights the company’s dedication to innovation and quality control in biopharmaceutical manufacturing.
Tags: biotech, quality control, antibody-drug conjugates
Read more on asiae.co.kr